Latest Investigation News

Tennant Minerals has completed a $2.8 million placement to accelerate drilling and development at its Bluebird copper-gold-bismuth discovery, aiming to extend high-grade zones and explore new targets along a 2.5km corridor.

Neurotech International has locked in a $3.15 million secured loan against its anticipated R&D tax incentives to fund pivotal Phase III autism trials and ongoing operations.

Sunshine Metals has boosted its Liontown gold-silver resource in Queensland, increasing contained gold by 13%, silver by 21%, and overall tonnes by 28%, underpinning plans for mid-2027 gold production at the Mt Moss facility.

Cyclopharm has landed a major US expansion deal with University Hospitals Cleveland, deploying Technegas® across 11 sites simultaneously and boosting its recurring revenue base in the Midwest.

The Federal Treasurer has barred three foreign shareholders from exercising voting rights in Northern Minerals due to non-compliance with mandated share divestments, intensifying regulatory oversight amid ongoing FIRB investigations.

Neurotech International has secured FDA clearance for its Investigational New Drug application for NTI164, enabling clinical development in the US and advancing its global registration and commercialisation plans.

Macro Metals has secured 100% of the Yandi South Iron Ore Project, adding a historical 4.28Mt resource and promising exploration upside near major Pilbara mines. The deal complements its existing Extension Iron Project stake and mining services contracts.

G11 Resources has confirmed a significant 90m zone of hydrothermal alteration at its Zig Zag target in Tasmania, with further drilling and surveys underway to test the open-ended geophysical anomaly.

McLaren Minerals has wrapped up its largest-ever drilling campaign at the McLaren Titanium Project on schedule and within budget, setting the stage for a Mineral Resource update and maiden Ore Reserve estimate.

Vectus Biosystems has appointed Cardinal Health Regulatory Services as its US regulatory agent to manage FDA submissions for its lead fibrosis drug VB0004, marking a pivotal step towards clinical development in the US.

Immutep’s INSIGHT-003 trial shows promising overall survival in first-line non-squamous NSCLC, yet the Phase III TACTI-004 trial was discontinued following a futility analysis. Ongoing root cause investigations aim to clarify the divergent outcomes.

Manuka Resources has lifted the Wonawinta Silver Mine's Ore Reserve by 28%, underpinning its imminent restart of silver and gold production with upgraded plant facilities and contracted mining operations.